Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial.

Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial. J Crohns Colitis. 2016 Aug; 10(8):925-33.

View in: PubMed

subject areas

Adolescent
Adult
Aged
Aged, 80 and over
Anti-Inflammatory Agents, Non-Steroidal
Colitis, Ulcerative
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Follow-Up Studies
Humans
Induction Chemotherapy
Maintenance Chemotherapy
Male
Mesalamine
Middle Aged
Prospective Studies
Treatment Outcome
Young Adult

authors with profiles

David T. Rubin